Kenvue Inc. (NYSE:KVUE) Shares Sold by Daymark Wealth Partners LLC

Daymark Wealth Partners LLC reduced its stake in Kenvue Inc. (NYSE:KVUE) by 37.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,448 shares of the company’s stock after selling 5,611 shares during the period. Daymark Wealth Partners LLC’s holdings in Kenvue were worth $202,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Grove Bank & Trust raised its position in Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares in the last quarter. Riverview Trust Co acquired a new position in shares of Kenvue during the third quarter worth about $30,000. Fortitude Family Office LLC increased its stake in shares of Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after buying an additional 777 shares during the period. Ashton Thomas Securities LLC purchased a new position in Kenvue in the third quarter worth approximately $35,000. Finally, Versant Capital Management Inc grew its holdings in Kenvue by 300.8% during the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after acquiring an additional 1,441 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

KVUE has been the topic of a number of analyst reports. Piper Sandler upgraded shares of Kenvue from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $21.00 to $26.00 in a report on Monday, January 6th. Citigroup decreased their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Wednesday, January 15th. Royal Bank of Canada upgraded Kenvue from a “hold” rating to a “moderate buy” rating in a report on Monday, December 9th. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and decreased their target price for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. Finally, Barclays dropped their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $23.08.

Kenvue Stock Performance

Shares of Kenvue stock opened at $20.79 on Friday. The firm’s fifty day simple moving average is $22.14 and its 200-day simple moving average is $21.75. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The stock has a market capitalization of $39.85 billion, a price-to-earnings ratio of 37.79, a PEG ratio of 1.99 and a beta of 1.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. During the same period in the previous year, the business posted $0.31 earnings per share. Kenvue’s quarterly revenue was down .4% on a year-over-year basis. As a group, equities analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be given a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.95%. Kenvue’s payout ratio is 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.